ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT. // European Urology Focus. – URL: https://www.sciencedirect.com/science/article/pii/S2405456926001197?dgcid=rss_sd_all
ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT. European Urology Focus. https://www.sciencedirect.com/science/article/pii/S2405456926001197?dgcid=rss_sd_all
“ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT.” European Urology Focus.
@article{article93799,
title = {ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT},
journal = {European Urology Focus},
url = {https://www.sciencedirect.com/science/article/pii/S2405456926001197?dgcid=rss_sd_all}
}